Tranquilliser and functional foodstuff. RU patent 2446793.

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are offered an anxiolytic and/or antidepressant drug which contains vitamin K₂ in the amount of 10 mcg to 100 mcg as an active component, a food additive for the same application and an appropriate method of treating.

EFFECT: vitamin K₂ (preferentially - menaquinone-4 and/or menaquinone-7) is safe to use for a long period of time and shows tranquilising action, particularly bland, antidepressant and antistress action.

4 cl, 2 dwg

IPC classes for russian patent Tranquilliser and functional foodstuff. RU patent 2446793. (RU 2446793):

A61P25/22 - Anxiolytics

A61K31/122 -

A23L1/302 -

A23L1/30 - containing additives (A23L0001308000 takes precedence);;

Another patents in same IPC classes:

Pharmaceutical composition for treating anxiety / 2444369
Invention refers to pharmaceutical industry, particularly to a composition for treating anxiety disorder. The pharmaceutical composition for treating anxiety disorder containing ginsenoside having Rg1 and Rb1; and a glycyrrhizic acid derivative being specified in a group consisting of glycyrrhizic acid, glycyrrhetinic acid and their combination taken in specific proportions. The pharmaceutical composition for treating anxiety disorder containing ginseng and liquorice taken in certain proportions.

Method of individual psychologic rehabilitation of patients with prosthetic heart valves / 2444288
Invention relates to medicine, cardiology and cardiac surgery, and can be used for psychological rehabilitation of patients with prosthetic heart valves (PHV). Method includes studying index of development of anxious disorders in pre-operational and post-operational periods and carrying out procedures for patients who have undergone cardiosurgical operations, including drug therapy. In determination of anxiety higher level is considered to be from 31 points and higher, additionally performed are point massage and muscular relaxation successively with groups of muscles of arms, forearms, face, neck, shoulder girdle, abdomen, hips, ankles and feet. Relaxation with each group of muscles is performed for 5-10 seconds 2-3 times per week.

Composition for injections based on crystalline β-modification of 7-brom-1,3-dihydro-5-(2-chlorphenyl)-2h-1,4-benzodiazepin-2-one exhibiting tranquilising action and method for preparing it / 2440120
Group of inventions relates to medicine, in particular to pharmacy. A composition for injections exhibiting tranquilising action contains the ingredients in the following proportions, wt %: crystalline β-modification of 7-brom-1,3-dihydro-5-(2-chlorphenyl)-2H-1,4-benzodiazepin-2-one - 0.05-0.15, polyvinylpyrrolidone - 0.50-1.20, "Tween-80" - 2.00-10.00, glycerine - 5.00-15.00, sodium pyrosulphite - 0.30-1.20, sodium hydrate solution - to pH 6.0-7.5, water - the rest. A method for preparing the composition consist in the fact that "Tween-80" and glycerine are mixed, heated to 70-90°C, and crystalline β-modification of 7-brom-1,3-dihydro-5-(2-chlorphenyl)-2H-1,4-benzodiazepin-2-one is dissolved. The prepared mixture is poured in the mixed aqueous solution of sodium pyrosulphite and polyvinylpyrrolidone heated to 40-90°C, cooled to room temperature, filtered, reduced to pH 6.0-7.5 with sodium hydrate solution, bottled and sterilised.

Mglur5 modulators / 2439068
Described are novel compounds of general formula I:

Agent showing serotonin 5-ht<sub>3</sub>-receptor antagonist properties

Agent showing serotonin 5-ht₃-receptor antagonist properties / 2438669
What is offered is a biologically active substance showing 5-HT3-serotonin receptor antagonist properties, 1-piperidinopropyl-2-(4-fluorophenyl)imidazo[1,2-a]benzimidazole of formula I. The compound has been known as a local anaesthetic. There are shown evident 5-HT3-antagonist properties of the compound in the macromolar concentration equal to the reference preparation ondansetron with the compound of formula I being safer.

Medication possessing antidepressive, anxiolytic and nootropic action / 2437659
Invention relates to pharmaceutical industry and medicine. Claimed is application of N-carbamoyl-4-(n-methoxyphenyl)-2-pyrrolidone of structural formula as means possessing antidepressive, anxiolytic and nootropic action. This low-toxic compound (LD50 2263.88 mg/kg) possesses high antidepressive, anxiolytic and nootropic activity, affect of which is not accompanied by hypnosedative phenomena, or reduction of mental and physical work ability.

Thiophenyl and pyrrolyl azepines as serotonin 5ht<sub>2c</sub> receptor ligands and use thereof

Thiophenyl and pyrrolyl azepines as serotonin 5ht_2c receptor ligands and use thereof / 2434872
Invention relates to compounds of formula , where X denotes S; R1 and R2 taken together with atoms to which they are bonded form a 5-member carbocycle, substituted with up to two substitutes selected from alkyl and CF3; R3 is selected from a group consisting of a hydrogen atom and C1-8-alkyl; R3a denotes a hydrogen atom; R4 denotes a hydrogen atom; R4a denotes a hydrogen atom; R5 denotes a hydrogen atom; R5a denotes a hydrogen atom; R6 denotes a hydrogen atom; R6a denotes a hydrogen atom; R7 denotes a hydrogen atom; or pharmaceutically acceptable salts thereof. The invention also relates to compounds of the given formula, compounds selected from the group, as well as a pharmaceutical composition.

Crystalline beta-modification of 7-bromo-1,3-dihydro-5-(2-chlorophenyl)-2h-1,4-benzodiazepin-2-one and synthesis method thereof / 2430094
Described is a novel crystalline β-modification of 7-bromo-1,3-dihydro-5-(2-chlorophenyl)-2H-1,4-benzodiazepin-2-one (phenazepam) and synthesis method thereof, which can be used in pharmaceutical industry and medicine as a tranquilliser. Said novel crystalline β-modification of 7-bromo-1,3-dihydro-5-(2-chlorophenyl)-2H-1,4-benzodiazepin-2-one is characterised by certain interplanar spacing (A0) and corresponding intensity and parameters of the crystal lattice, given in the claims.

S-adenosylmethionine compositions for peroral application / 2427376
Claimed are dietary and/or nutriceutic pharmaceutical composition for peroral application which contains S-adenosylmethi-onine-para-toluolsulfonate (SAMe) in combination with inositol and/or ino-sitol-1-phosphate and pharmaceutically acceptable excipients, in which at least one of and pharmaceutically acceptable excipients represents magnesium oxide in concentration from approximately 1.0 to approximately 10.0% of composition weight (versions), method of its obtaining, method of stabilisation of hard food and/or nutriceutic pharmaceutical composition based on SAMe-para-toluolsulfonate by application of inositol and/or inositol-1-phosphate, application of SAMe-para-toluolsulfonate in combination with inositol and/or inositol-1-phosphate for obtaining composition for treatment of depressive states and panic syndromes.

Alkyl sulphonamide quinolines with affinity to nk-3 receptors / 2421447
Compound is ((S)-1-phenyl-propyl)-amide 3-(methane sulphonyl amino)-2-phenyl- quinoline-4-carboxylic acid, stereoisomer, enantiomer or pharmaceutically acceptable salt thereof. The invention also relates to a pharmaceutical composition based on the disclosed compound.

Sun-protective compositions containing carotenoids / 2446792
Group of inventions refers to medicine, cosmetology, and may be used for treating or preventing light exposure on a human or an animal. That is ensured by a photoprotective composition, including in the form of a cosmetic preparation containing the carotenoid compound diadinoxantine or its pharmaceutically acceptable prodrug or salt. There are also offered a method for diadinoxantine recovery from algae, as well as a method for producing a photoprotective or photoprotected product involving application or impregnation of said product with photoprotective composition containing diadinoxantine.

Method of treating iga-nephropathy / 2445080
Invention refers to medicine, namely nephrology and can be used for treating the patients with IgA-nephropathies with infectious pathogens detected in renal tissue. For this purpose provided cytomegalovirus and/or Epstein-Barr virus, or their combination with Chlamidia thrahomitis bacterium are found in biopsy renal tissue, Reaferon 400000-600000 units daily and Amixin 125 mg every second day are administered; the therapeutic course is 2.5-4 months.

6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone composition and method for preparing it / 2445079
Invention refers to chemical-pharmaceutical industry, and concerns a liquid 6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone composition which is characterised by high bioavailability and prolonged shelf life. The composition contains an active substance - 6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone, a nonionic surfactant, an antioxidant, a preservative agent, a fat-soluble emulsion stabiliser, water-soluble cellulose derivatives, water-soluble emulsion and water stabiliser. Also, there is offered a method for preparing the composition which consists in the fact that certain amounts of the nonionic surfactant and the antioxidant are mixed, heated to 40-120°C; the required amounts of the fat-soluble emulsion stabiliser and 6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone are dissolved in the prepared solution; the prepared mixture is cooled to 30-60°C and in through mixing added to the mixed solution of the cellulose derivatives, the water-soluble emulsion stabiliser and the preservative agent pre-heated to 30-60°C.

Anthracenedione compounds / 2443415
Present invention refers to pharmaceutics and medicine, and concerns a composition for inflammatory bowel disease or irritable colon syndrome containing an effective amount of the composition of formula .

Composition with 6-decaprnyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone for parenteral introduction and method of its obtaining / 2433820
Invention relates to medicine and describes composition of 6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone, which contains 0.2-15% 6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone, 0.2-40% solubilising agent and 45-99.6% water.

Testosterone amplifier / 2431475
Invention refers to testosterone amplifier, to a drug which prevents, relieves and/or treats symptoms or diseases caused by testosterone deficiency and to an additive for treating menopausal disorders in males. As an active ingredient, vitamin K (vitamin K2, menaquinone-4 or menaquinone-7) 10 mcg to 100 mg is used.

Transmucosal introduction of 2,3-dimethoxy-5-methyl-6- (10-hydroxydecyl)-1,4-benzochinone / 2429830
What is offered is application of idebenone for preparing a drug for transmucosal introductions for treating mitochondral, neurological and neuromotor diseases, and the drug is introduced through a nasal mucosa, an oral mucosa or a colon mucosa.

New cyclohexenone compounds of antrodia camphorata and their application / 2422431
Present invention refers to new compounds of formula (1) in which X and Y can be oxygen or sulphur, each R1, R2 and R3 are hydrogen atom, methyl or (CH2)m-CH3, and m=1-12, n=1-12 inhibiting tumour cell growth, to a based pharmaceutical compositions (versions), and also to methods of inhibiting breast, liver and prostate cancer cell growth. The offered compounds are recovered from Antrodia camphorata.

Application of 2-hydroxy-3-methyl-6-(1-methylethenyl)cyclohex-3-enone as analgesic / 2421213
Offered is an application of 2-hydroxy-3-methyl-6-(1-methylethenyl)cyclo-hex-3-enone (compound of formula 1) as an analgesic. The agent can be produced of an available natural compound α-pinene.

Application of 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyclohexandione in treatment of parkinson's disease / 2420272
Claimed is application of 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyclohexandione in production of medication in treatment of neurodegenerative disease, Parkinson's disease, as well as pharmaceutical compositions and sets (versions) of similar purpose, which include said compound.

Method for production of lactic acid bacteriae useful for k2 vitamin producing and their application for food products preparation / 2446211
Method for production of Lactococcus lactis strain version producing, under standard fermentation conditions, a quantity of vitamin K2 exceeding that produced by the stock/parent bacterial strain inoculated under the same conditions approximately 1.2 times, the said method including, at least: a) inoculation of the sock bacterial strain under standard fermentation conditions in a cultural medium causing a change in the oxidation-reduction state of a cell containing bacitracin or a peroxide and b) selection of the strain version if producing a quantity of vitamin K2 exceeding that produced by the stock/parent bacterial strain inoculated under the same conditions approximately 1.2 times. Lactococcus lactis subsp.cremoris 1-3557 strain deposited in Collection CNCN of Pasteur Institute on 20.01.2006 and Lactococcus lactis subsp.cremoris 1-3558 strain deposited in Collection CNCM of Pasteur Institute on 20.01.2006 produce at least 1.2 times more vitamin K2 than the stock/parent bacterial strain inoculated under the same conditions. Additionally, the invention deals with a lactic acid starter containing at least one of the above strains and to the method for preparation of a cultured milk product containing the above strain and/or the lactic acid starter.